DL
VIRX

Delta Lloyd’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Delta Lloyd’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-476
Closed -$519K – 583
2013
Q2 		$519K Buy
+476
New +$530K 0.02% 307

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Delta Lloyd's VIRX Position: Q3 2013 in Review

Delta Lloyd sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2013, closing a stake of 476 shares — an estimated $519K sold.

Delta Lloyd first reported a position in VIRX in Q2 2013 and held it in 1 quarter. The position peaked at $519K in Q2 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q3 2013.

  • Delta Lloyd reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Delta Lloyd sold 476 Viracta Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $519K.
  • Delta Lloyd first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Delta Lloyd's Viracta Therapeutics, Inc. Common Stock position peaked at $519K in Q2 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2013.

Based on Delta Lloyd's 13F filing for Q3 2013, filed 24 Oct 2013.